166 related articles for article (PubMed ID: 25888628)
1. Manipulation of prostate cancer metastasis by locus-specific modification of the CRMP4 promoter region using chimeric TALE DNA methyltransferase and demethylase.
Li K; Pang J; Cheng H; Liu WP; Di JM; Xiao HJ; Luo Y; Zhang H; Huang WT; Chen MK; Li LY; Shao CK; Feng YH; Gao X
Oncotarget; 2015 Apr; 6(12):10030-44. PubMed ID: 25888628
[TBL] [Abstract][Full Text] [Related]
2. Calpain-2 triggers prostate cancer metastasis via enhancing CRMP4 promoter methylation through NF-κB/DNMT1 signaling pathway.
Gao X; Mao YH; Xiao C; Li K; Liu W; Li LY; Pang J
Prostate; 2018 Jun; 78(9):682-690. PubMed ID: 29601651
[TBL] [Abstract][Full Text] [Related]
3. Expression profiling identifies new function of collapsin response mediator protein 4 as a metastasis-suppressor in prostate cancer.
Gao X; Pang J; Li LY; Liu WP; Di JM; Sun QP; Fang YQ; Liu XP; Pu XY; He D; Li MT; Su ZL; Li BY
Oncogene; 2010 Aug; 29(32):4555-66. PubMed ID: 20543870
[TBL] [Abstract][Full Text] [Related]
4. Upregulation of CRMP4, a new prostate cancer metastasis suppressor gene, inhibits tumor growth in a nude mouse intratibial injection model.
Zhou W; Xie P; Pang M; Yang B; Fang Y; Shu T; Liu C; Wang X; Zhang L; Li S; Rong L
Int J Oncol; 2015 Jan; 46(1):290-8. PubMed ID: 25338524
[TBL] [Abstract][Full Text] [Related]
5. Regulation of the transcriptional coactivator FHL2 licenses activation of the androgen receptor in castrate-resistant prostate cancer.
McGrath MJ; Binge LC; Sriratana A; Wang H; Robinson PA; Pook D; Fedele CG; Brown S; Dyson JM; Cottle DL; Cowling BS; Niranjan B; Risbridger GP; Mitchell CA
Cancer Res; 2013 Aug; 73(16):5066-79. PubMed ID: 23801747
[TBL] [Abstract][Full Text] [Related]
6. Prospective Study of CRMP4 Promoter Methylation in Prostate Biopsies as a Predictor For Lymph Node Metastases.
Gao X; Li LY; Rassler J; Pang J; Chen MK; Liu WP; Chen Z; Ren SC; Zhou FJ; Xie KJ; Zhou X; Qian HJ; Bai XZ; Liu JM; Yang JG; He D; Shao CK; Su ZL; Wang J; Qiu JG; Ling L
J Natl Cancer Inst; 2017 Jan; 109(6):. PubMed ID: 28122909
[TBL] [Abstract][Full Text] [Related]
7. Effect of histone deacetylase and DNA methyltransferase inhibitors on the expression of the androgen receptor gene in androgen-independent prostate cancer cell lines.
Fialova B; Smesny Trtkova K; Paskova L; Langova K; Kolar Z
Oncol Rep; 2013 May; 29(5):2039-45. PubMed ID: 23503510
[TBL] [Abstract][Full Text] [Related]
8. SMYD3 as an oncogenic driver in prostate cancer by stimulation of androgen receptor transcription.
Liu C; Wang C; Wang K; Liu L; Shen Q; Yan K; Sun X; Chen J; Liu J; Ren H; Liu H; Xu Z; Hu S; Xu D; Fan Y
J Natl Cancer Inst; 2013 Nov; 105(22):1719-28. PubMed ID: 24174655
[TBL] [Abstract][Full Text] [Related]
9. Suppression of Prostate Cancer Metastasis by DPYSL3-Targeted saRNA.
Li B; Li C
Adv Exp Med Biol; 2017; 983():207-216. PubMed ID: 28639202
[TBL] [Abstract][Full Text] [Related]
10. Gene methylation in gastric cancer.
Qu Y; Dang S; Hou P
Clin Chim Acta; 2013 Sep; 424():53-65. PubMed ID: 23669186
[TBL] [Abstract][Full Text] [Related]
11. Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer.
Ogishima T; Shiina H; Breault JE; Tabatabai L; Bassett WW; Enokida H; Li LC; Kawakami T; Urakami S; Ribeiro-Filho LA; Terashima M; Fujime M; Igawa M; Dahiya R
Clin Cancer Res; 2005 Feb; 11(3):1028-36. PubMed ID: 15709168
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo.
Wang M; Liu X; Guo J; Weng X; Jiang G; Wang Z; He L
Biochem Biophys Res Commun; 2015 Nov; 467(2):310-5. PubMed ID: 26435505
[TBL] [Abstract][Full Text] [Related]
13. Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer.
Jarrard DF; Bova GS; Ewing CM; Pin SS; Nguyen SH; Baylin SB; Cairns P; Sidransky D; Herman JG; Isaacs WB
Genes Chromosomes Cancer; 1997 Jun; 19(2):90-6. PubMed ID: 9171999
[TBL] [Abstract][Full Text] [Related]
14. DNA methylation paradigm shift: 15-lipoxygenase-1 upregulation in prostatic intraepithelial neoplasia and prostate cancer by atypical promoter hypermethylation.
Kelavkar UP; Harya NS; Hutzley J; Bacich DJ; Monzon FA; Chandran U; Dhir R; O'Keefe DS
Prostaglandins Other Lipid Mediat; 2007 Jan; 82(1-4):185-97. PubMed ID: 17164146
[TBL] [Abstract][Full Text] [Related]
15. p21WAF1/CIP1 gene is inactivated in metastatic prostatic cancer cell lines by promoter methylation.
Bott SR; Arya M; Kirby RS; Williamson M
Prostate Cancer Prostatic Dis; 2005; 8(4):321-6. PubMed ID: 16276353
[TBL] [Abstract][Full Text] [Related]
16. Cytosine methylation represses glutathione S-transferase P1 (GSTP1) gene expression in human prostate cancer cells.
Singal R; van Wert J; Bashambu M
Cancer Res; 2001 Jun; 61(12):4820-6. PubMed ID: 11406558
[TBL] [Abstract][Full Text] [Related]
17. Change in gene expression profiles of secreted frizzled-related proteins (SFRPs) by sodium butyrate in gastric cancers: induction of promoter demethylation and histone modification causing inhibition of Wnt signaling.
Shin H; Kim JH; Lee YS; Lee YC
Int J Oncol; 2012 May; 40(5):1533-42. PubMed ID: 22246241
[TBL] [Abstract][Full Text] [Related]
18. KLF9, a transcription factor induced in flutamide-caused cell apoptosis, inhibits AKT activation and suppresses tumor growth of prostate cancer cells.
Shen P; Sun J; Xu G; Zhang L; Yang Z; Xia S; Wang Y; Liu Y; Shi G
Prostate; 2014 Jun; 74(9):946-58. PubMed ID: 24737412
[TBL] [Abstract][Full Text] [Related]
19. Tpl2 induces castration resistant prostate cancer progression and metastasis.
Lee HW; Cho HJ; Lee SJ; Song HJ; Cho HJ; Park MC; Seol HJ; Lee JI; Kim S; Lee HM; Choi HY; Nam DH; Joo KM
Int J Cancer; 2015 May; 136(9):2065-77. PubMed ID: 25274482
[TBL] [Abstract][Full Text] [Related]
20. Hypermethylation of the GABRE~miR-452~miR-224 promoter in prostate cancer predicts biochemical recurrence after radical prostatectomy.
Kristensen H; Haldrup C; Strand S; Mundbjerg K; Mortensen MM; Thorsen K; Ostenfeld MS; Wild PJ; Arsov C; Goering W; Visakorpi T; Egevad L; Lindberg J; Grönberg H; Høyer S; Borre M; Ørntoft TF; Sørensen KD
Clin Cancer Res; 2014 Apr; 20(8):2169-81. PubMed ID: 24737792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
